Abstracts tagged "filgotinib"

Abstract Number: 1698 • ACR Convergence 2021
Integrated Safety Analysis Update for Filgotinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Receiving Treatment over a Median of 2.2 Years
Kevin Winthrop¹, Yoshiya Tanaka², Tsutomu Takeuchi³, Alan Kivitz⁴, Mark Genovese⁵, Alena Pechonkina⁶, Franziska Matzkies⁶, Beatrix Bartok⁷, Kun Chen⁶, Deyuan Jiang⁶, Iyabode Tiamiyu⁶, Robin Besuyen⁸, Sander Strengholt⁹, Gerd Burmester¹⁰ and Jacques-Eric Gottenberg¹¹, ¹Oregon Health & Science University, Portland, OR, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Div. Rheumatology, Keio University, Tokyo, Japan, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Gilead Sciences, Inc., Sunnyvale, CA, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Gilead Sciences, Inc., La Jolla, CA, ⁸Galapagos BV, Leiden, Netherlands, ⁹Galapagos, BV, New York, NY, ¹⁰Charité University Medicine Berlin, Berlin, Germany, ¹¹National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) significantly improved signs and symptoms of RA in Phase 2 and 3 trials,1–5 and FIL is…
Abstract Number: 1710 • ACR Convergence 2021
Clinical Outcomes of MTX-Naïve RA Patients on Filgotinib Long-term Extension Trial Initially on FIL or MTX During Phase 3 Parent Trial
Daniel Aletaha¹, Rene Westhovens², Tatsuya Atsumi³, YingMeei Tan⁴, Alena Pechonkina⁵, Qi Gong⁵, Vijay Rajendran⁶, Sander Strengholt⁷ and Gerd Burmester⁸, ¹Medical University Vienna, Vienna, Austria, ²University Hospitals KU Leuven, Maaseik, Belgium, ³Hokkaido University, Sapporo, Japan, ⁴Gilead Sciences, Inc, San Diego, CA, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Galapagos, BV, New York, NY, ⁸Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) is approved for treatment of moderately to severely active RA in Europe and Japan. In this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].